Share this article
CAMBRIDGE, Mass., May 4, 2021 /PRNewswire/
Theseus Pharmaceuticals, a biotechnology company shaping the future of targeted oncology by developing best-in-class, pan-variant kinase inhibitors, today announced the appointment of Tim Clackson, Ph.D., as Chief Executive Officer and as a member of the Company s Board of Directors. He succeeds interim CEO Iain Dukes, D.Phil., Theseus Co-Founder and OrbiMed Venture Partner, who will serve as Theseus Executive Chairman. I am thrilled to join the team of R&D leaders at Theseus, who have a proven track record and share my passion for oncology innovation, motivated by our direct experience helping change patients lives with targeted therapies, said Dr. Clackson. Collectively, we are leveraging decades of insight to develop innovative medicines to confront the scourge of treatment resistance. With the backing of our top-tier investors, I look forward to realizing Theseus vision to build an industry leading precisi